沙库巴曲缬沙坦联合达格列净治疗冠心病合并心力衰竭患者的临床疗效

doi:10.3969/j.issn.1671-7171.2025.08.012

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1245 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨沙库巴曲缬沙坦联合达格列净治疗冠心病(CHD)合并心力衰竭(HF)患者的临床疗效。【方法】前瞻性选取2020年9月至2023年9月本院收治的82例CHD合并HF患者,采用随机数字表法分为观察组和对照组,每组41例。对照组给予沙库巴曲缬沙坦治疗,观察组给予沙库巴曲缬沙坦联合达格列净治疗。比较两组临床疗效、心功能指标[左心室收缩末内径(LVESD)、左心室舒张末内径(LVEDD)、左室射血分数(LVEF)、6 min步行距离(6MWD)]、实验室指标[脑钠肽(BNP)、超敏C反应蛋白(hs-CRP)、一氧化氮(NO)、内皮素-1(ET-1)]、患者1年内HF再住院率及不良反应发生情况。【结果】观察组总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,两组LVEF、6MWD高于治疗前,LVEDD、LVESD低于治疗前,观察组LVEF、6MWD高于对照组,LVEDD、LVESD低于对照组,差异有统计学意义(P<0.05)。治疗后,两组血清BNP、hs-CRP、ET-1水平低于治疗前,且观察组低于对照组(P<0.05);两组血清NO水平高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05)。观察组因HF再住院率低于对照组,差异有统计学意义(P=0.022)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。【结论】沙库巴曲缬沙坦联合达格列净治疗CHD合并HF的临床疗效较好,可改善患者心功能及血管内皮功能,抑制炎症反应,降低患者HF再住院率,安全性良好。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	李香娜

关键词 ：冠心病, 心力衰竭, 缬沙坦, 药物疗法,联合

Abstract：【Objective】To explore the clinical efficacy of sacubitril valsartan combined with dapagliflozin in the treatment of coronary heart disease (CHD) complicated with heart failure (HF). 【Methods】 A total of 82 patients with CHD complicated with HF admitted to our hospital from September 2020 to September 2023 were prospectively selected and divided into the observation group and the control group using a random number table method, with 41 patients in each group. The control group was treated with sacubitril valsartan, while the observation group was treated with sacubitril valsartan combined with dapagliflozin. The two groups were compared in terms of clinical efficacy, cardiac function indicators [left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), left ventricular ejection fraction (LVEF) and 6-minute walking distance (6MWD)], laboratory indicators [brain natriuretic peptide (BNP), high-sensitivity C-reactive protein (hs-CRP), nitric oxide (NO), endothelin-1 (ET-1)], 1-year readmission rate due to HF, and incidence of adverse reactions. 【Results】The total effective rate of the observation group was higher than that of the control group, with a statistically significant difference (P<0.05). After treatment, LVEF and 6MWD in both groups were higher than those before treatment, while LVEDD and LVESD were lower than those before treatment; LVEF and 6MWD in the observation group were higher than those in the control group, and LVEDD and LVESD were lower than those in the control group, with statistically significant differences (P<0.05). After treatment, the serum levels of BNP, hs-CRP, and ET-1 in both groups were lower than those before treatment, and the observation group had lower levels than the control group; the serum NO level in both groups was higher than that before treatment, and the observation group had a higher level than the control group, with statistically significant differences (P<0.05). The readmission rate due to HF in the observation group was lower than that in the control group, with a statistically significant difference (P=0.022). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05). 【Conclusion】Sacubitril valsartan combined with dapagliflozin has a good clinical efficacy in the treatment of CHD complicated with HF. It improves patients' cardiac function and vascular endothelial function, inhibits inflammatory response, reduces the readmission rate of patients, and has good safety.

Key words： Coronary Disease Heart Failure Valsartan Drug Therapy, Combination

收稿日期: 2024-02-29

中图分类号:

R541.4

引用本文:

李香娜. 沙库巴曲缬沙坦联合达格列净治疗冠心病合并心力衰竭患者的临床疗效[J]. 医学临床研究, 2025, 42(8): 1335-1338.
LI Xiangna. Clinical Efficacy of Sacubitril Valsartan Combined with Dapagliflozin in the Treatment of Coronary Heart Disease Complicated with Heart Failure. JOURNAL OF CLINICAL RESEARCH, 2025, 42(8): 1335-1338.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2025.08.012 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2025/V42/I8/1335

[1] ZHAO G L, ZHANG H Y, WANG Y, et al. Effects of levocarnitine on cardiac function, urinary albumin, hs-CRP, BNP, and troponin in patients with coronary heart disease and heart failure[J].Hellenic J Cardiol,2020,61(2):99-102.
[2] 孟雅杰, 陈嘉怡, 李敬超, 等. 沙库巴曲缬沙坦钠片治疗冠心病合并慢性心力衰竭的疗效及对患者心功能与炎性因子水平的影响[J].海南医学, 2023,34(5):621-624.
[3] HUSSAIN M, ATIF M, BABAR M, et al. Comparison of efficacy and safety profile of empagliflozin versus dapagliflozin as add on therapy in type 2 diabetic patients[J].J Ayub Med Coll Abbottabad,2021,33(4):593-597.
[4] 王晶, 刘易婷, 刘哲. 达格列净和维格列汀对糖尿病合并冠心病老年患者血糖、血管内皮功能及心功能的影响[J].陕西医学杂志, 2022,51(12):1581-1584.
[5] 李雪博, 范燕宾, 杜睿, 等. 达格列净、恩格列净及卡格列净在心肌梗死后预防心力衰竭患者的临床研究[J].中国临床药理学杂志, 2023,39(22):3204-3208.
[6] 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 冠心病诊断与治疗指南[J].中华心血管病杂志, 2007,35(3):195-206.
[7] 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志, 2014,42(2):98-122.
[8] 顾丽萍, 胡菁, 严蜀华. 美托洛尔与曲美他嗪治疗老年冠心病心力衰竭的疗效及对患者心功能、心肌重塑和炎症因子的影响[J].中国老年学杂志, 2017,37(1):89-91.
[9] 吴景煌, 黄修献, 陈天德. 沙库巴曲缬沙坦治疗心力衰竭临床观察[J].中国药业, 2023,32(5):104-107.
[10] SCOTT D SOLOMON, JOHN J V MCMURRAY, BRIAN CLAGGETT, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction[J].N Engl J Med,2022,387(12):1089-1098.
[11] 蔡月娣, 梁碧, 黄彩英. 达格列净治疗老年2型糖尿病患者的疗效及对患者胰岛β细胞功能、心功能的影响[J].海南医学, 2023,34(2):190-193.
[12] ZHOU Q L, PAN L L, XUE R C, et al. The anti-microbial peptide LL-37/CRAMP levels are associated with acute heart failure and can attenuate cardiac dysfunction in multiple preclinical models of heart failure[J].Theranostics,2020,10(14):6167-6181.
[13] XU W D, TAO H X, HU D, et al. Serum BNP level expression in pediatric patients with ventricular septal defects and its relation with cardiac function and heart failure[J].Minerva Pediatr (Torino),2022,74(2):132-135.
[14] PAKHTUSOV N N, IUSUPOVA A O,PRIVALOVA E V, et al. Endothelial dysfunction and inflammation in patients with non-obstructive coronary arteries[J].Kardiologiia,2021,61(1):52-58.